CINECA IRIS Institutional Research Information System

PRATESI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.379
AS - Asia 4.032
EU - Europa 2.622
SA - Sud America 851
AF - Africa 228
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 4
Totale 13.121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.251
CN - Cina 1.221
IT - Italia 1.206
SG - Singapore 1.183
BR - Brasile 676
HK - Hong Kong 605
VN - Vietnam 443
SE - Svezia 277
DE - Germania 210
FI - Finlandia 165
FR - Francia 151
BG - Bulgaria 147
CI - Costa d'Avorio 128
KR - Corea 124
JP - Giappone 113
AT - Austria 97
RU - Federazione Russa 92
GB - Regno Unito 74
IN - India 71
AR - Argentina 70
TR - Turchia 65
CA - Canada 63
BD - Bangladesh 36
MX - Messico 33
IQ - Iraq 32
PL - Polonia 30
EC - Ecuador 29
CH - Svizzera 28
SN - Senegal 28
ES - Italia 25
NL - Olanda 24
CZ - Repubblica Ceca 21
ID - Indonesia 21
UZ - Uzbekistan 17
VE - Venezuela 16
PK - Pakistan 15
UA - Ucraina 14
CL - Cile 13
CO - Colombia 13
MA - Marocco 13
PY - Paraguay 13
ZA - Sudafrica 13
BE - Belgio 11
NG - Nigeria 10
AL - Albania 9
KE - Kenya 9
SA - Arabia Saudita 9
DZ - Algeria 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
BO - Bolivia 7
EG - Egitto 7
IE - Irlanda 7
LT - Lituania 7
JO - Giordania 6
TN - Tunisia 6
TW - Taiwan 6
CR - Costa Rica 5
HN - Honduras 5
IL - Israele 5
KZ - Kazakistan 5
MY - Malesia 5
OM - Oman 5
PE - Perù 5
RO - Romania 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
AZ - Azerbaigian 4
GR - Grecia 4
JM - Giamaica 4
PH - Filippine 4
PS - Palestinian Territory 4
RS - Serbia 4
DK - Danimarca 3
DO - Repubblica Dominicana 3
EU - Europa 3
HU - Ungheria 3
IR - Iran 3
KW - Kuwait 3
PA - Panama 3
TH - Thailandia 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BS - Bahamas 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
NP - Nepal 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
BN - Brunei Darussalam 1
BY - Bielorussia 1
CD - Congo 1
GA - Gabon 1
GI - Gibilterra 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 13.112
Salva come PNG Salva come JPEG
Città #
Ashburn 706
Singapore 650
Hong Kong 598
Shanghai 522
Santa Clara 442
Fairfield 437
Dallas 368
San Jose 345
Milan 278
Woodbridge 274
Houston 198
Chandler 193
Seattle 191
Hefei 172
Wilmington 165
Cambridge 163
Sofia 147
Beijing 143
New York 140
Council Bluffs 137
Ho Chi Minh City 133
Helsinki 132
Abidjan 128
Seoul 122
Pisa 117
Livorno 116
Los Angeles 115
Ann Arbor 109
Tokyo 103
Boardman 93
Vienna 82
Serra 78
Princeton 76
Florence 75
Hanoi 72
Lauterbourg 68
Bremen 61
Munich 61
Lawrence 58
São Paulo 56
Rome 55
Medford 52
Istanbul 42
Frankfurt am Main 39
Redondo Beach 35
Buffalo 31
San Diego 30
Dakar 28
London 27
Rio de Janeiro 25
Dong Ket 22
Turku 20
Ogden 19
Ottawa 19
Vicopisano 19
Warsaw 19
Bern 18
Da Nang 18
Fuzhou 18
Kent 18
Nuremberg 17
Porto Alegre 17
Tashkent 17
Washington 17
Fort Wayne 16
San Giuliano Terme 16
Baltimore 15
Salvador 15
Brno 14
Chennai 14
Haiphong 14
Mexico City 13
Paris 13
Amsterdam 12
Belo Horizonte 12
Boulder 12
Des Moines 12
Baghdad 11
Biên Hòa 11
Brasília 11
Curitiba 11
Guayaquil 11
Norwalk 11
Wuhan 11
Atlanta 10
Brussels 10
Cascina 10
Chicago 10
Denver 10
Quanzhou 10
Trento 10
Brantford 9
Buenos Aires 9
Lagos 9
Lucca 9
Montreal 9
Nanjing 9
Pune 9
Quito 9
Betim 8
Totale 9.151
Salva come PNG Salva come JPEG
Nome #
Alkyne Functionalization of a Photoactivated Ruthenium Polypyridyl Complex for Click-Enabled Serum Albumin Interaction Studies 434
Two mixed valence diruthenium(ii,iii) isomeric complexes show different anticancer properties 254
New copper(II)/cyclic tetrapeptide system that easily oxidizes to copper(III) under atmospheric oxygen 251
Photocytotoxic Pt(iv) complexes as prospective anticancer agents 249
Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells 220
When ferrocene and diiron organometallics meet: triiron vinyliminium complexes exhibit strong cytotoxicity and cancer cell selectivity 218
A mixed-valence diruthenium(ii,iii) complex endowed with high stability: from experimental evidence to theoretical interpretation 215
Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent 208
Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation 208
Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region 204
Auranofin, Et3PAuCl, and Et3PAuI Are Highly Cytotoxic on Colorectal Cancer Cells: A Chemical and Biological Study 199
Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments 182
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 182
An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies 181
A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies 180
Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes 176
Synthesis, Characterization and Photoactivation Studies on the Novel Pt(IV)-Based [Pt(OCOCH3)3(phterpy)] Complex 176
Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis 175
New gold carbene complexes as candidate anticancer agents 174
Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues 173
The leading established metal-based drugs: a revisitation of their relevant physico-chemical data 172
Design and Solid Phase Synthesis of New DOTA Conjugated (+)-Biotin Dimers Planned to Develop Molecular Weight-Tuned Avidin Oligomers 166
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 165
Exploring the interaction between a fluorescent Ag(I)-biscarbene complex and non-canonical DNA structures: a multi-technique investigation 165
Role of the (pseudo)halido ligand in ruthenium(ii): p -cymene a-amino acid complexes in speciation, protein reactivity and cytotoxicity 164
Ruthenium arene complexes with triphenylphosphane ligands: Cytotoxicity towards pancreatic cancer cells, interaction with model proteins, and effect of ethacrynic acid substitution 162
ESI MS studies highlight the selective interaction of Auranofin with protein free thiols 161
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 160
Medicinal Hypervalent Tellurium Prodrugs Bearing Different Ligands: A Comparative Study of the Chemical Profiles of AS101 and Its Halido Replaced Analogues 159
The cisplatin/serum albumin system: A reappraisal 159
A focus on the biological targets for coinage metal-NHCs as potential anticancer complexes 158
Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study 153
Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear Selenocysteine containing C-terminal peptide hTrxR(488-499): An ESI-MS investigation 150
The NAMI A-human ferritin system: A biophysical characterization 149
Thermodynamic Evaluation of the Interactions between Anticancer Pt(II) Complexes and Model Proteins 149
Description of a Non-Canonical AsPt Blue Species Originating from the Aerobic Oxidation of AP-1 in Aqueous Solution 147
The New Pyrimido-indole Compound CD-160130 Preferentially Inhibits the KV11.1B Isoform and Produces Antileukemic Effects Without Cardio-toxicity 147
Reactions of Auranofin and Its Pseudohalide Derivatives with Serum Albumin Investigated through ESI-Q-TOF MS 146
Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with a L-alanyl-based ligand 146
Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEt3)I: A Theoretical and Experimental Study 145
Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation 144
Mass spectrometry and metallomics: stability and binding site location in the Cyt c-CDDP model system 140
On the Different Mode of Action of Au(I)/Ag(I)-NHC Bis-Anthracenyl Complexes Towards Selected Target Biomolecules 140
Structure of a new stable Cu(III)/cyclopeptide complex by Cu K-edge XAS study 138
Highlights of New Strategies to Increase the Efficacy of Transition Metal Complexes for Cancer Treatments 137
Exploiting the Chemical Diversity of Metal Compounds as a Source of Novel Anti-COVID-19 Drugs 136
Synthesis, Chemical Characterization, and Biological Evaluation of Hydrophilic Gold(I) and Silver(I) N-Heterocyclic Carbenes as Potential Anticancer Agents 135
Structural Characterization of a Gold/Serum Albumin Complex 134
Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin 134
Evaluation of Auranofin Loading within Ferritin Nanocages 133
Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth - An Investigation of the Activation Mechanism and Their Nanoformulation 133
Mass Spectrometry and Metallomics: binding site location in the Cyt c-CDDP model system 131
Impact of ring size on the copper(II) coordination abilities of cyclic tetrapeptides 128
ESI–MS studies of the reactions of novel platinum(II) complexes containing O,O′-chelated acetylacetonate and sulfur ligands with selected model proteins 127
Reactions of medicinal gold(III) compounds with proteins and peptides explored by electrospray ionization mass spectrometry and complementary biophysical methods 127
An unprecedented palladium-arsenic catalytic cycle for nitriles hydration 126
Dioxygen oxidation Cu(II) → Cu(III) in the copper complex of cyclo (Lys- d His-βAla-His): A case study by EXAFS and XANES approach 126
The choice of μ-vinyliminium ligand substituents is key to optimize the antiproliferative activity of related diiron complexes 124
Non‐medical applications of inorganic medicines. A switch based on mechanistic knowledge 124
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 124
Ru(CO)x-core complexes with selected azoles: Synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells 124
DOTA-Derivatives of Octreotide Dicarba-Analogs with High Affinity for Somatostatin sst2,5 Receptors 123
Mechanistic Evaluations of the Effects of Auranofin Triethylphosphine Replacement with a Trimethylphosphite Moiety 123
Reevaluating the Mechanistic Insights of α-TOS-Bearing Pt(IV) Anticancer Complexes: A New Perspective from a More In-Depth Knowledge 122
Computationally enhanced X-ray diffraction analysis of a gold(III) complex interacting with the human telomeric DNA G-quadruplex. Unravelling non-unique ligand positioning 121
Short-chain oligopeptides with copper(II) binding properties: the impact of specific structural modifications on the copper(II) coordination abilities 119
Pd(II)/1,10-phenanthroline complexes bearing arene ligands: On the role of N- vs O-coordination to tune their cellular activity and binding ability towards DNA and RNA 119
Protein interactions of dirhodium tetraacetate: a structural study 117
Metallo therapeutics for COVID-19. Exploiting metal-based compounds for the discovery of new antiviral drugs 117
Cytotoxic auranofin analogues bearing phosphine, arsine and stibine ligands: A study on the possible role of the ligand on the biological activity 116
Synthesis of dicarba-cyclooctapeptide Somatostatin analogs by conventional and MW-assisted RCM: A study about the impact of the configuration at Cα of selected amino acids 114
Strategies for the improvement of metal-based chemotherapeutic treatments 114
Native mass spectrometry of human carbonic anhydrase I and its inhibitor complexes 111
A biophysical study of the interactions of palladium(II), platinum(II) and gold(III) complexes of aminopyridyl-2,2'-bipyridine ligands with RNAs and other nucleic acid structures 109
Iron Binding in the Ferroxidase Site of Human Mitochondrial Ferritin 109
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 106
Trans-Pd(II) complexes: A different approach for the development of promising anticancer drugs 103
Arsenoplatin-ferritin nanocage: Structure and cytotoxicity 103
The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct 103
Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds 97
A new stable Copper(III)/Cyclopeptide complex: structural characterization by XANES and EXAFS studies 93
A new stable Copper(III)/Cyclopeptide complex: structural characterization by XANES and EXAFS studies 87
Direct detection of iron clusters in L ferritins through ESI-MS experiments 84
Anticancer diiron vinyliminium complexes: A structure– activity relationship study 78
Editorial: Spotlight on Europe - chemical sciences 2023 74
Hydrophobic gold nanoparticles coupled with fluorescent dyes: A smart tool for optoelectronic applications 74
Editorial: The Golden Future in Medicinal Chemistry: Perspectives and Resources From Old and New Gold-Based Drug Candidates 74
Structure of a New Stable Cu(III)/Cyclopeptide Complex by Cu K-Edge XAS Study 72
null 71
null 66
Is the Next Cisplatin Already in Our Laboratory? 65
Protein-Based Delivery Systems for Anticancer Metallodrugs: Structure and Biological Activity of the Oxaliplatin/β-Lactoglobulin Adduct 62
Procedimento catalitico per la preparazione di ammidi 60
null 55
Redefining platinum(IV) chemotherapy: α-tocopherol succinate functionalization and nanoparticle encapsulation to improve cisplatin- and oxaliplatin-based therapies 51
Mechanistic Fingerprints from Chloride to Iodide: Halide vs. Ammonia Release in Platinum Anticancer Complexes 42
null 41
Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells 40
Ligand‐Dependent DNA Binding and Cytotoxicity of Palladium(II) Complexes 37
Thiosugar-functionalized gold(I)-NHC complexes as selective anticancer agents for potential targeted therapy 33
Totale 13.552
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.590
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.590
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021105 0 0 0 0 0 0 0 0 0 0 0 105
2021/2022724 17 23 11 35 138 111 46 26 72 20 67 158
2022/20231.275 130 120 92 97 73 117 35 59 418 39 48 47
2023/20241.063 115 106 144 77 150 161 71 26 19 22 73 99
2024/20253.724 21 100 18 159 305 326 750 161 378 430 394 682
2025/20264.624 266 581 607 693 324 311 612 318 322 350 141 99
Totale 13.602